Payment overview · 2025
General Payments
$170.95
10 reported records · 7 companies
Healthcare provider profile · identity verified
Cierra Johnson, MD
Allopathic & Osteopathic Physicians|Family Medicine · SALINA, KS · NPI 1013327659
Verified facts
What the public records show
CMS Open Payments records show Cierra Johnson, MD received $170.95 in general payments during 2025 across 10 reported records.
GlaxoSmithKline, LLC. accounted for 27.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Shingrix.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trelegy Ellipta by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $46.69 | 27.3% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $42.68 | 25.0% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $19.46 | 11.4% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $18.22 | 10.7% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $14.91 | 8.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.56 | 8.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.43 | 8.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $170.95 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $42.68 | 2 | 2025 |
Source payment records
|
|||||
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $32.26 | 2 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $30.65 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $19.46 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $18.22 | 1 | 2025 |
Source payment records
|
|||||
| PEDIARIX Normalized: pediarix |
Biological | GlaxoSmithKline, LLC. | $16.22 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $14.91 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.56 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.56 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.43 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.43 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.43 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 48 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 28 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
28 | 22 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 354 | 89 |
| Lisinopril | Lisinopril | 343 | 93 |
| Atorvastatin Calcium | Atorvastatin Calcium | 253 | 66 |
| Amlodipine Besylate | Amlodipine Besylate | 215 | 57 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 214 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 209 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 199 | 52 |
| Losartan Potassium | Losartan Potassium | 199 | 52 |
| Warfarin Sodium | Warfarin Sodium | 180 | 11 |
| Simvastatin | Simvastatin | 175 | 41 |
| Omeprazole | Omeprazole | 167 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 164 | 41 |
| Metformin Hcl | Metformin Hcl | 153 | 36 |
| Potassium Chloride | Potassium Chloride | 148 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 147 | 36 |
| Gabapentin | Gabapentin | 140 | 38 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 140 | 35 |
| Furosemide | Furosemide | 114 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 113 | 24 |
| Sertraline Hcl | Sertraline Hcl | 113 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 107 | 18 |
| Atenolol | Atenolol | 102 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 93 | 15 |
| Alendronate Sodium | Alendronate Sodium | 78 | 22 |
| Meloxicam | Meloxicam | 74 | 21 |
| Cephalexin | Cephalexin | 70 | 19 |
| Eliquis | Apixaban | 66 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 65 | 13 |
| Montelukast Sodium | Montelukast Sodium | 64 | 17 |
| Trulicity | Dulaglutide | 62 | suppressed |
| Spironolactone | Spironolactone | 58 | 15 |
| Glipizide Er | Glipizide | 52 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 50 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | 14 |
| Famotidine | Famotidine | 48 | suppressed |
| Ozempic | Semaglutide | 48 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 48 | suppressed |
| Prednisone | Prednisone | 46 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 45 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 44 | suppressed |
| Allopurinol | Allopurinol | 43 | 11 |
| Celecoxib | Celecoxib | 42 | suppressed |
| Mounjaro | Tirzepatide | 41 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 39 | suppressed |
| Myrbetriq | Mirabegron | 37 | suppressed |
| Pregabalin | Pregabalin | 37 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 37 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 35 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 33 | 14 |
| Carvedilol | Carvedilol | 32 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 32 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Estradiol | Estradiol | 31 | 11 |
| Fluconazole | Fluconazole | 31 | 12 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 28 | 22 |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 27 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 25 | 25 |
| Jardiance | Empagliflozin | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 24 | 23 |
| Doxepin Hcl | Doxepin Hcl | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Lorazepam | Lorazepam | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Glipizide | Glipizide | 22 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 21 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 15 |
| Arnuity Ellipta | Fluticasone Furoate | 19 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Mesalamine | Mesalamine | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Nystatin | Nystatin | 16 | 11 |
| Valsartan | Valsartan | 16 | suppressed |
| Azithromycin | Azithromycin | 15 | 13 |
| Baclofen | Baclofen | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $170.95 · 10 records | GlaxoSmithKline, LLC. | AIRSUPRA, AREXVY, BEXSERO, Cologuard Collection Kit, Korlym, LEQVIO, Ozempic, PEDIARIX, PENMENVY, Rybelsus, SHINGRIX, WATCHMAN FLX | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error